Dr. Miljkovic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
BG 10 RM 4N115
Bethesda, MD 20814Phone+1 301-250-5216
Summary
- Dr. Milos Miljkovic is an oncologist in Bethesda, MD. He received his medical degree from University of Belgrade Faculty of Medicine and has been in practice 9 years. He also speaks multiple languages, including Serbian. He specializes in hematologic oncology and is experienced in hematology, oncology, and lymphoma. He has more than 30 publications and over 500 citings.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2017
Sinai Hospital of BaltimoreChief Residency, Internal Medicine, 2013 - 2014- Sinai Hospital of BaltimoreResidency, Internal Medicine, 2010 - 2013
University of Belgrade Faculty of MedicineClass of 2008
Certifications & Licensure
MD State Medical License 2016 - 2025
DC State Medical License 2024 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Start of enrollment: 2017 Jan 19
- Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia Start of enrollment: 2019 Jul 11
- Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Start of enrollment: 2019 Jun 07
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.Max J Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon
Leukemia & Lymphoma. 2024-07-01 - 2 citationsMethodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders.Nadia Güell, Pablo Mozas, Alba Jimenez-Rueda, Milos Miljkovic, Jordi Juncà
Critical Reviews in Clinical Laboratory Sciences. 2023-03-01 - 11 citationsInterleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.Milos D Miljkovic, Sigrid P Dubois, Jürgen R Müller, Bonita Bryant, Elaine Ma
Blood Advances. 2023-02-14
Abstracts/Posters
- Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...Milos D. Miljkovic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Flavopiridol Elicits Poor Response in Mantle Cell Lymphoma, DLBCLJuly 18th, 2019
Professional Memberships
- Member
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
Other Languages
- Serbian
External Links
- Websitehttp://miljko.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
